Hydrocortisone in Severe Community-Acquired Pneumonia

Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. A total of 800 patients had undergone... read more

Hydrocortisone in Severe Community-Acquired Pneumonia

No Benefits For Using 4-Factor Prothrombin Complex Concentrate (4F-PCC) in Trauma Patients

Early administration of 4-factor prothrombin complex concentrate (4F-PCC) was of no benefit to patients with trauma at risk of massive transfusion, the randomized PROCOAG trial from France showed. Among over 300 patients... read more

No Benefits For Using 4-Factor Prothrombin Complex Concentrate (4F-PCC) in Trauma Patients

Oral PCSK9 Inhibitor Could Help Reduce LDL-C by 60%

New research from a phase 2b trial presented at American College of Cardiology meeting (ACC) 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular... read more

Oral PCSK9 Inhibitor Could Help Reduce LDL-C by 60%

Postoperative Pulmonary Complications in the ENIGMA II Trial

Respiratory complications remain among the most common and serious adverse outcomes of major surgery. In the Australian and New Zealand Audit of Surgical Mortality, postoperative pneumonia accounted for 44% of infective... read more

Postoperative Pulmonary Complications in the ENIGMA II Trial

The CLOVERS Trial: Does Nothing Matter in Sepsis?

The CLOVERS trials is an open label RCT that did not demonstrate any difference (beneficial or harmful) from using a restrictive fluid strategy over a liberal fluid strategy in sepsis-induced hypotension. Do whatever... read more

The CLOVERS Trial: Does Nothing Matter in Sepsis?

Delirium Prevention in the ICU: Melatonin or Ramelteon

Melatonin modulates the circadian rhythm and has been studied as a preventive measure against the development of delirium in hospitalized patients. Such an effect may be more evident in patients admitted to the ICU, but findings... read more

Delirium Prevention in the ICU: Melatonin or Ramelteon

Baricitinib or Tocilizumab for Severe COVID-19 Treatment

Pharmacologic treatment of COVID-19 has continued to evolve since the onset of the pandemic, and yet many questions remain about optimal treatment. Medicine strives to provide evidence-based guidance on treatments, but... read more

Baricitinib or Tocilizumab for Severe COVID-19 Treatment

Remote Ischemic Conditioning in Septic Shock

The treatment known as RECO did not significantly reduce the severity of organ failure as measured by the mean daily SOFA (sequential organ failure assessment) score from the start of the study to day 4 in patients with septic... read more

Remote Ischemic Conditioning in Septic Shock

Molnupiravir Improves Recovery Time in COVID-19 Patients at High Risk of Severe Outcomes

This analysis of a large randomized trial involving people who are at high risk of experiencing severe outcomes from COVID-19 and who had been vaccinated against SARS-CoV-2 infection found that adding molnupiravir to usual... read more

Molnupiravir Improves Recovery Time in COVID-19 Patients at High Risk of Severe Outcomes

Bayesian Reanalysis of the Standard vs. Accelerated Initiation of RRT in AKI Trial

Timing of initiation of kidney-replacement therapy (KRT) in critically ill patients remains controversial. The Standard versus Accelerated Initiation of Renal-Replacement Therapy (RRT) in Acute Kidney Injury (STARRT-AKI)... read more

Bayesian Reanalysis of the Standard vs. Accelerated Initiation of RRT in AKI Trial

Evaluation of abdominal compression-decompression combined with chest compression CPR performed by a new device

Compression–decompression cardiopulmonary resuscitation (CO-CPR) was more beneficial than standard cardiopulmonary resuscitation (STD-CPR) in terms of survival benefits in patients who have suffered out-of-hospital cardiac... read more

Evaluation of abdominal compression-decompression combined with chest compression CPR performed by a new device

Surfactant Therapies for Pediatric ARDS

We advocate for well-designed preclinical and explanatory clinical studies to investigate the use of surfactant for pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome. Given the accumulating knowledge... read more

Surfactant Therapies for Pediatric ARDS

Endoscopic Sleeve Gastroplasty for Treatment of Obesity

Endoscopic sleeve gastroplasty (ESG) is a safe intervention that resulted in significant weight loss, maintained at 104 weeks, with important improvements in metabolic comorbidities. ESG should be considered as a synergistic... read more

Endoscopic Sleeve Gastroplasty for Treatment of Obesity

Baricitinib in COVID-19 Patients

In patients hospitalized with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomized evidence to date suggests... read more

Baricitinib in COVID-19 Patients

Optimizing the Design and Analysis of Future AKI Trials

Acute kidney injury (AKI) is a complex clinical syndrome associated with an increased risk of morbidity and mortality, particularly in critically ill and perioperative patient populations. Most AKI clinical trials have... read more

Optimizing the Design and Analysis of Future AKI Trials